FDA Eases Biosimilar Approval Process as Market Generates $56 Billion in Savings

The U.S. Food and Drug Administration has moved to ease biosimilar development and approval procedures as these therapies have generated over $56 billion in savings since their first launch in 2015. The regulatory shift comes amid growing recognition of biosimilars' strategic value in containing medical cost inflation driven by expensive biopharmaceuticals and new drugs.

The FDA issued draft guidance in late 2025 that proposed the elimination of comparative efficacy studies for most biosimilar applications. This change is intended to streamline the approval process by focusing on analytical data rather than costly clinical trials. The FDA estimated that this shift could save manufacturers up to $100 million in development costs per product and reduce development timelines by as much as 50%.

By early 2026, biosimilars accounted for approximately 23% of the total biologics market in the United States. Despite this growth, stakeholders identified a "biosimilar void" that could result in $232 billion in missed savings over the next 10 years if current development and adoption trends do not accelerate. While more than 110 biologics were set to lose patent protection over the next decade, only 10% of those products had biosimilars currently in development.

Nearly 25 new biosimilars were expected to receive FDA approval between 2026 and 2027, targeting therapeutic areas such as oncology, immunology, and retina. The impact of biosimilars varies by specialty, with oncology remaining the most mature market, achieving an average 81% market share within 5 years of initial competition.

A survey of 101 physician practices in late 2025 revealed high levels of clinical confidence alongside persistent operational concerns. Approximately 99% of participating providers reported they felt confident explaining biosimilars to their patients. Adoption was primarily driven by clinical data (56%) and payer requirements (50%). However, physicians identified significant points of hesitancy, with the leading concern (cited by 53% of respondents) involving the non-medical switching of a long-term, stable patient from a reference biologic to a biosimilar. Reimbursement complexities were also noted as a barrier by 34% of surveyed practices, and 94% of respondents stated that a stable reimbursement rate for medical benefit biosimilars was an important factor in their utilization decisions.

The launch of adalimumab biosimilars provided a critical real-world test for market disruption. Research through April 2025 identified a notable "switchback" trend, showing that 13.2% of patients who initially transitioned to an adalimumab biosimilar eventually reverted to the reference biologic, Humira. This phenomenon was particularly prevalent among older adults and patients with rheumatoid arthritis or ankylosing spondylitis, with nearly 40% of these switchbacks occurring within the first 30 days of treatment. Experts attributed this trend largely to the nocebo effect—a psychological phenomenon where a patient's negative perceptions or anxiety regarding a new medication led to perceived worsened clinical outcomes or adverse events.

Community gastroenterology practices faced increasing operational complexity as they managed the simultaneous launch of 3 different biosimilar classes: infliximab, adalimumab, and ustekinumab. For these providers, the primary challenges included navigating frequently changing payer formularies and managing the logistics of a growing inventory of similar but non-identical products.

The long-term viability of the biosimilar market depends on aligning stakeholder incentives and stabilizing reimbursement models. Proactive policy measures are necessary to ensure that the health care system can realize the billions of dollars in potential savings offered by these therapies.